Search research articles
Contact Us
Filters
Showing results (121-130 of 175) with videos related to
Page
of 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2015
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5
Karim Fizazi, Robert Jones, Stephane Oudard, et al.
British Journal of Clinical Pharmacology
|
January 14, 2022
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
Ronald de Wit, Thomas Powles, Daniel Castellano, et al.
International Journal of Cancer
|
September 23, 2014
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel
Michel D Wissing, Jules L L M Coenen, Pieter van den Berg, et al.
European Urology
|
August 15, 2016
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer
Nicholas J Vogelzang, Karim Fizazi, John M Burke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2016
Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study
Annemieke J M Nieuweboer, Anne-Joy M de Graan, Paul Hamberg, et al.
Critical Reviews in Oncology/Hematology
|
August 30, 2008
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach
John M Fitzpatrick, John Anderson, Cora N Sternberg, et al.
The Lancet. Oncology
|
May 29, 2021
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
Arjun V Balar, Ashish M Kamat, Girish S Kulkarni, et al.
European Urology
|
August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial
Ronald de Wit, David J Vaughn, Yves Fradet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
David J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
Cancers
|
August 23, 2019
Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
Ingeborg E de Kruijff, Anieta M Sieuwerts, Wendy Onstenk, et al.
Page
of 18
Search research articles
Search
Showing results (121-130 of 175) with videos related to
Sort By:
Page
of 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2015
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5
Karim Fizazi, Robert Jones, Stephane Oudard, et al.
British Journal of Clinical Pharmacology
|
January 14, 2022
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
Ronald de Wit, Thomas Powles, Daniel Castellano, et al.
International Journal of Cancer
|
September 23, 2014
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel
Michel D Wissing, Jules L L M Coenen, Pieter van den Berg, et al.
European Urology
|
August 15, 2016
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer
Nicholas J Vogelzang, Karim Fizazi, John M Burke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2016
Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study
Annemieke J M Nieuweboer, Anne-Joy M de Graan, Paul Hamberg, et al.
Critical Reviews in Oncology/Hematology
|
August 30, 2008
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach
John M Fitzpatrick, John Anderson, Cora N Sternberg, et al.
The Lancet. Oncology
|
May 29, 2021
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
Arjun V Balar, Ashish M Kamat, Girish S Kulkarni, et al.
European Urology
|
August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial
Ronald de Wit, David J Vaughn, Yves Fradet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
David J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
Cancers
|
August 23, 2019
Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
Ingeborg E de Kruijff, Anieta M Sieuwerts, Wendy Onstenk, et al.
Page
of 18